Clinical Trials Are the Fastest Path to Data Revenue

When health tech teams brainstorm data monetization, they usually start with the glamorous end: selling de-identified datasets to pharma. That market is real, but it's slow to enter. De-identification validation, buyer trust, and multi-quarter procurement all sit between you and the first check.

There's a faster door, and most teams walk right past it: clinical trials.

The enrollment problem is your opportunity

Trial recruitment is chronically, expensively broken. In inflammatory bowel disease, enrollment has run at roughly 0.08 to 0.12 patients per site per year, and the field's own literature points to patient registries and health record systems as the leading fix. Sponsors routinely pay for screening infrastructure that still fails to fill studies. Timelines slip by quarters, and every slipped quarter costs sponsors real money.

Now look at what you have: a defined patient population, engaged through a product they actually use, with current clinical signal rather than a three-year-old snapshot. To a sponsor or CRO struggling to fill a study, that's not a dataset. That's the scarcest resource in their world: findable, reachable, pre-screened patients.

What sponsors actually buy

Trial support revenue comes in a few forms, roughly in order of how fast you can get to them:

1. Patient identification. Matching your population against a trial's inclusion and exclusion criteria and surfacing eligible candidates. Contracts here typically start in the five figures, and they close much faster than data sales because the sponsor's pain is immediate.
2. Recruitment and referral. Using the engagement channel you already have (your app, your monthly touchpoint) to put trial opportunities in front of eligible patients, with consent handled properly.
3. Retention and real-world follow-up. The same engagement engine that recruited patients keeps them in the study and captures outcomes afterward.

Notice what's driving the value in every case: engagement. Any broker can produce a list. You can produce patients who answer.

The flywheel

Done well, this becomes self-reinforcing. You market relevant trials to your patients, which is itself a service to them, since access to trials is something patients actively want. Enrollments build your track record with sponsors. That track record wins the next trial contract, which gives your patients access to more opportunities, which deepens engagement, which makes your cohort more valuable. Each side of the flywheel pushes the other.

The quiet second payoff

Here's the strategic part most teams miss: to do patient identification credibly, you must organize your data against real trial criteria. Structured disease severity, treatment history, comorbidities, current status. That structuring work is precisely what a future real-world data buyer needs too.

In other words, trials revenue funds your data-readiness work, and the data-readiness work matures your long-term asset. You're not choosing between near-term and long-term monetization; the near-term play is the long-term preparation. I've broken down where that long-term path leads in What Buyers Actually Pay for De-Identified Real-World Data, and the full sequencing logic in How Health Tech Companies Actually Monetize Their Data.

Where to start

Pick one active, recruiting trial in your disease area. Run your population against its actual inclusion and exclusion criteria. Count the gaps: the fields you don't capture, the consent language you'd need. That single exercise tells you your real distance from revenue, and it's the first thing I run in a Data Strategy & Monetization engagement.

The dataset you're proud of is the byproduct. The engaged patient is the product.